Patent ID: 7947257
Filing Date: 2011-05-24
Classification: A61K,A61P

Abstract:
1. A method of administering granisetron or a pharmaceutically acceptable salt thereof to a patient in need thereof, which method comprises intranasally administering a composition in the form of an aqueous solution for intranasal administration consisting essentially of granisetron or a pharmaceutically acceptable salt thereof, chitosan, a salt or a derivative thereof, wherein the derivative is selected from an ester, ether or other derivative of chitosan formed by bonding at least one of an acyl and an alkyl group with at least one of the hydroxyl groups, but not the amino groups of chitosan, and optionally, at least one osmolality adjusting agent, and wherein the chitosan, the salt or a derivative thereof is present in an amount sufficient to provide a time to maximum plasma concentration (T max ) of granisetron or a pharmaceutically acceptable salt thereof shorter than the T max for the granisetron or a pharmaceutically acceptable salt thereof in a corresponding composition not including the chitosan, salt or a derivative thereof.